{
    "clinical_study": {
        "@rank": "105914", 
        "arm_group": {
            "arm_group_label": "Eltrombopag", 
            "arm_group_type": "Experimental", 
            "description": "Pediatric patients undergoing allogeneic UCB transplantation will receive eltrombopag from day +1 until platelet count has exceeded 50,000/microliter for 14 consecutive days without platelet transfusion.\nStarting doses are 100 mg/d for children >40 kg body weight (BW), 50 mg/d for children 20-40 kg BW, and 2 mg/kg/d for children <20 kg BW.\nIf unsupported platelet count has not reached the threshold of 20,000/microliter, doses will be escalated every 2 weeks up to maximal doses of 200 mg/d for children \u2265 40 kg BW, 150 mg/d for children 20-40 kg BW and 3.5 mg/kg for children <20 kg BW."
        }, 
        "brief_summary": {
            "textblock": "Platelet recovery is significantly hampered following umbilical cord blood transplantation\n      (UCB). Thus, after UCB transplantations, patients are platelet transfusion-dependent for\n      prolong periods of time.\n\n      Eltrombopag is a thrombopoietin-receptor agonist that initiates thrombopoietin-receptor\n      signaling and thereby induces proliferation and maturation of megakaryocytes.\n\n      We will evaluate the safety and efficacy of eltrombopag for enhancing platelet engraftment\n      in pediatric patients undergoing cord blood transplantation."
        }, 
        "brief_title": "Eltrombopag for Enhancing Platelet Engraftment in Pediatric Patients Undergoing Cord Blood Transplantation", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Pediatric Patients Undergoing Allogeneic Cord Blood Transplantation.", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient \u2265 1 year and < 18 years old.\n\n          2. Patients receiving unmanipulated single or double UCB allogeneic grafts.\n\n          3. Malignant and non malignant indications for transplantation.\n\n          4. Myeloablative and reduced intensity conditioning regimens.\n\n          5. Patients must meet all other pre-transplantation criteria of the transplantation\n             center including acceptable tests of heart, liver, kidney, and lung function\n             (standard screening for transplantation per PI, and co-investigators).\n\n          6. Written informed must be obtained from the patient's guardian, and accompanying\n             informed assent from the patient for children over 6 years old.\n\n          7. Able to comply with study protocol.\n\n        Exclusion Criteria:\n\n          1. Indications for transplantation\n\n               1. Patients with primary myelofibrosis.\n\n               2. French-American-British classification (FAB)M7 acute myeloid leukemia. Acute\n                  leukemia  secondary to a myeloproliferative neoplasm.\n\n               3. Patients with persistent acute leukemia (>5% bone marrow blasts) at the time of\n                  transplantation.\n\n          2. Patients with prior thromboembolic event. Patients with previous catheter related\n             thrombosis will be eligible if more than 3 months elapsed.\n\n          3. Hypersensitivity to eltrombopag.\n\n          4. Liver enzymes abnormalities:\n\n        Alanine aminotransferase (ALT) levels > 3 times the upper limit of normal (ULN) or serum\n        bilirubin > 1.5 ULN (unless due to Gilbert's syndrome or hemolytic bilirubin).\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01940562", 
            "org_study_id": "0195-13"
        }, 
        "intervention": {
            "arm_group_label": "Eltrombopag", 
            "description": "Children \u2265= 40 kg BW:\nFrom day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d (maximal dose).\nChildren 20-40 kg BW:\nFrom day +1, start eltrombopag 50 mg/d. If primary end point not reached on day +14, then from day +15 - 75 mg/d. If primary end point not reached on day +28 then from day +29 - 100 mg/d.If primary end point not reached on day +42, then from day +43 and on - 150 mg/d (maximal dose).\nChildren < 20 kg BW:\nFrom day +1, start eltrombopag - 2 mg/kg/d. If primary end point not reached on day +14, then from day +15 - 3 mg/kg/d. If primary end point not reached on day +28 then from day +29 - 3.5 mg/kg (maximal dose).\nIf present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets.", 
            "intervention_name": "eltrombopag", 
            "intervention_type": "Drug", 
            "other_name": "Revolade"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "cord blood transplantation", 
            "platelets", 
            "eltrombopag"
        ], 
        "lastchanged_date": "September 8, 2013", 
        "location": {
            "contact": {
                "email": "jstein@clalit.org.il", 
                "last_name": "Jerry Stein, MD", 
                "phone": "972-50-4057148"
            }, 
            "facility": {
                "address": {
                    "city": "Petah Tikva", 
                    "country": "Israel", 
                    "zip": "49202"
                }, 
                "name": "Schneider Children's Medical Center of Israel"
            }, 
            "investigator": {
                "last_name": "Jerry Stein, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "Eltrombopag for Enhancing Platelet Engraftment in Pediatric Patients Undergoing Cord Blood Transplantation", 
        "other_outcome": [
            {
                "description": "Number of participants with any grade 3/4 adverse event as a measure of safety and tolerability.", 
                "measure": "Any grade 3/4 adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Number of participants with a thromboembolic event as a measure of safety.", 
                "measure": "Thromboembolic events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "overall_contact": {
            "email": "moshey@clalit.org.il", 
            "last_name": "Moshe Yeshurun, MD", 
            "phone": "972-3-9378127"
        }, 
        "overall_contact_backup": {
            "email": "RonRa@clalit.org.il", 
            "last_name": "Ron Ram, MD", 
            "phone": "972-3-9378116"
        }, 
        "overall_official": {
            "affiliation": "Rabin Medical Center", 
            "last_name": "Moshe Yeshurun, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Platelet engraftment rate up to 50 days post transplantation, defined as the first of 7 consecutive days of an unsupported platelet count of at least 20,000/microliter.", 
            "safety_issue": "No", 
            "time_frame": "50 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01940562"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rabin Medical Center", 
            "investigator_full_name": "moshe yeshurun", 
            "investigator_title": "Head, BMT unit, Rabin Medical Center", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to partial platelet engraftment, defined as the first of 7 consecutive days of an unsupported platelet count of at least 20,000/microliter.", 
                "safety_issue": "No", 
                "time_frame": "180 days"
            }, 
            {
                "measure": "Time to sustained complete platelet engraftment defined as the first of 7 consecutive days of an unsupported platelet count of at least 50,000/microliter.", 
                "safety_issue": "No", 
                "time_frame": "180 days"
            }, 
            {
                "measure": "Complete platelet engraftment rates up to 50 days post transplantation defined as the first of 7 consecutive days of an unsupported platelet count of at least 50,000/microliter.", 
                "safety_issue": "No", 
                "time_frame": "50 days"
            }, 
            {
                "measure": "Time to neutrophil engraftment defined as the first of 3 consecutive days to achieve an absolute neutrophil count \u2265 500/microliter.", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }
        ], 
        "source": "Rabin Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "moshe yeshurun", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}